Next Article in Journal
Overview on the Mycotoxins Incidence in Serbia in the Period 2004–2016
Next Article in Special Issue
Botulinum Neurotoxin Diversity from a Gene-Centered View
Previous Article in Journal
Effects of Dietary Astaxanthin Supplementation on Energy Budget and Bioaccumulation in Procambarus clarkii (Girard, 1852) Crayfish under Microcystin-LR Stress
Previous Article in Special Issue
Light Chain Diversity among the Botulinum Neurotoxins
Open AccessReview

Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity

1
Ipsen Bioinnovation, 102 Park Drive, Milton Park, Abingdon OX14 4RY, UK
2
Ipsen Innovation, 5 Avenue du Canada, 91940 Les Ulis, France
*
Author to whom correspondence should be addressed.
Toxins 2018, 10(7), 278; https://doi.org/10.3390/toxins10070278
Received: 25 May 2018 / Revised: 29 June 2018 / Accepted: 1 July 2018 / Published: 4 July 2018
(This article belongs to the Special Issue Novel BoNTs and Toxin Engineering)
Botulinum neurotoxins (BoNTs) are highly successful protein therapeutics. Over 40 naturally occurring BoNTs have been described thus far and, of those, only 2 are commercially available for clinical use. Different members of the BoNT family present different biological properties but share a similar multi-domain structure at the molecular level. In nature, BoNTs are encoded by DNA in producing clostridial bacteria and, as such, are amenable to recombinant production through insertion of the coding DNA into other bacterial species. This, in turn, creates possibilities for protein engineering. Here, we review the production of BoNTs by the natural host and also recombinant production approaches utilised in the field. Applications of recombinant BoNT-production include the generation of BoNT-derived domain fragments, the creation of novel BoNTs with improved performance and enhanced therapeutic potential, as well as the advancement of BoNT vaccines. In this article, we discuss site directed mutagenesis, used to affect the biological properties of BoNTs, including approaches to alter their binding to neurons and to alter the specificity and kinetics of substrate cleavage. We also discuss the target secretion inhibitor (TSI) platform, in which the neuronal binding domain of BoNTs is substituted with an alternative cellular ligand to re-target the toxins to non-neuronal systems. Understanding and harnessing the potential of the biological diversity of natural BoNTs, together with the ability to engineer novel mutations and further changes to the protein structure, will provide the basis for increasing the scope of future BoNT-based therapeutics. View Full-Text
Keywords: recombinant; target secretion inhibitors; rational design; receptors; enzyme recombinant; target secretion inhibitors; rational design; receptors; enzyme
Show Figures

Graphical abstract

MDPI and ACS Style

Fonfria, E.; Elliott, M.; Beard, M.; Chaddock, J.A.; Krupp, J. Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity. Toxins 2018, 10, 278. https://doi.org/10.3390/toxins10070278

AMA Style

Fonfria E, Elliott M, Beard M, Chaddock JA, Krupp J. Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity. Toxins. 2018; 10(7):278. https://doi.org/10.3390/toxins10070278

Chicago/Turabian Style

Fonfria, Elena; Elliott, Mark; Beard, Matthew; Chaddock, John A.; Krupp, Johannes. 2018. "Engineering Botulinum Toxins to Improve and Expand Targeting and SNARE Cleavage Activity" Toxins 10, no. 7: 278. https://doi.org/10.3390/toxins10070278

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop